Retrospective Cohort Study
Copyright ©The Author(s) 2020.
World J Gastrointest Surg. Apr 27, 2020; 12(4): 138-148
Published online Apr 27, 2020. doi: 10.4240/wjgs.v12.i4.138
Table 1 Patients’ demographics and clinical characteristics in each group
Group W (n = 37)Group N (n = 53)Group MD (n = 20)Total (n = 110)
Patients’ characteristics
Age (yr, mean ± SD)71.4 ± 11.874.3 ± 13.673.7 ± 9.673.5 ± 12.5
Male/Female18/1928/2515/561/49
PS score (mean ± SD)1.6 ± 1.21.9 ± 1.22.3 ± 1.01.9 ± 1.2
Therapeutic intent
BTS19/37 (51.4%)32/53 (60.4%)10/20 (50%)61/110 (55.5%)
PAL18/37 (48.6%)21/53 (39.6%)10/20 (50%)49/110 (44.5%)
Tumor characteristics
Obstruction/tumor site
Right colon8/37 (21.6%)14/53 (26.4%)6/20 (30%)28/110 (25.4%)
Left colon27/37 (73.0%)38/53 (71.7%)10/20 (50%)75/110 (68.2%)
Rectum2/37 (5.4%)1/53 (1.9%)4/20 (20%)7/110 (6.4%)
Etiology of colorectal obstruction
Primary colorectal cancer30/37 (81.1%)49/53 (92.5%)13/20 (65%)92/110 (83.6%)
Metastatic lesion7/37 (18.9%)4/53 (7.5%)7/20 (35%)18/110 (16.4%)
Noncancerous stenosis0/37 (0%)0/53 (0%)0/20 (0%)0/110 (0%)
Stenosis length [cm, median (range)]5.0 (2.0-13.0)5.0 (2.0-11.0)6.2 (2.5-11.5)5.0 (2.0-13.0)
Table 2 Outcomes in each stent group, Group W, Group N, and Group MD
Group WGroup NGroup MDTotal
Technical success rate37/37 (100%)53/53 (100%)20/20 (100%)110/110 (100%)
Stent length
6 cm24/37 (64.9%)12/53 (22.6%)3/20 (15%)39/110 (35.5%)
8 cmNA17/53 (32.1%)7/20 (35%)24/110 (21.8%)
9 cm11/37 (29.7%)NANA11/110 (10.0%)
10 cmNA18/53 (34.0%)6/20 (30%)24/110 (21.8%)
12 cm2/37 (5.4%)6/53 (11.3%)4/20 (20%)12/110 (10.9%)
Stent diameter
18 mmNA6/53 (11.3%)NA6/110 (5.5%)
22 mm30/37 (81.1%)47/53 (88.7%)20/20 (100%)97/110 (88.2%)
25 mm7/37 (18.9%)NANA7/110 (6.3%)
Procedure time (min, mean ± SD)32.6 ± 14.033.6 ± 23.731.3 ± 11.233.0 ± 19.1
Clinical success rate33/37 (89.2%)51/53 (96.2%)20/20 (100%)104/110 (94.5%)
BTS19/19 (100%)31/32 (96.9%)10/10 (100%)60/61 (98.4%)
PAL14/18 (77.8%)20/21 (95.2%)10/10 (100%)44/49 (89.8%)
CROSS before stent placement (mean ± SD)1.6 ± 1.31.2 ± 1.01.4 ± 0.91.4 ± 1.1
012/37 (32.5%)10/53 (18.9%)3/20 (15%)25/110 (22.7%)
18/37 (21.6%)32/53 (60.4%)9/20 (45%)49/110(44.6%)
23/37 (8.1%)4/53 (7.5%)5/20 (25%)12/110 (10.9%)
313/37 (35.1%)5/53 (9.4 %)3/20 (15%)21/110 (19.1%)
41/37 (2.7%)2/53 (3.8%)0/20 (0%)3/110 (2.7%)
CROSS after stent placement (mean ± SD)3.8 ± 0.8a3.8 ± 0.7a3.8 ± 0.5a3.8 ± 0.7a
00/37 (0%)0/53 (0%)0/20 (0%)0/110 (0%)
13/37 (8.1%)2/53 (3.8%)0/20 (0%)5/110(4.6%)
20/37 (0%)2/53 (3.8%)1/20 (5.0%)3/110 (2.7%)
30/37 (0%)0/53 (0 %)2/20 (10%)2/110 (1.8%)
434/37 (91.9%)49/53 (92.4%)17/20 (85%)110/110 (90.9%)
Table 3 Early and late adverse events
Group WGroup NGroup MDTotal
Early (≤ 7 d)
Perforations0/37 (0%)2/53 (3.8%)10/20 (0%)2/110 (1.8%)
Bleeding0/37 (0%)0/53 (0%)0/20 (0%)0/110 (0%)
Poor expansion1/37 (2.7%)0/53 (0%)0/20 (0%)1/110 (0.9%)
Abdominal pain3/37 (8.1%)0/53 (0%)0/20 (0%)3/110 (2.7%)
Stent occlusion0/37 (0%)0/53 (0%)0/20 (0%)0/110 (0%)
Fever1/37 (2.7%)0/53 (0%)0/20 (0%)1/110 (0.9%)
Late (> 7 d)
Perforations4/36 (11.1%)a20/51 (0%)a0/20 (0%)4/107 (3.7%)
Bleeding0/36 (0%)0/51 (0%)0/20 (0%)0/107 (0%)
Stent migration0/36 (0%)0/51 (0%)0/20 (0%)0/107 (0%)
Abdominal pain0/36 (0%)0/51 (0%)0/20 (0%)0/107 (0%)
Stent occlusion1/36 (2.8%)2/51 (3.9%)0/20 (0%)3/107 (2.8%)